Finally, a GPR-TME classifier that can predict patient prognosis and assist in subsequent immunotherapy analysis was established by the combination of the above two risk profiles, and its value in terms of the prognosis and immunotherapy in patients with STS was assessed. The gene discussed is ALDH18A1; the disease is telomere syndrome.